Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Neurosci Res ; 78(5): 711-22, 2004 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-15478179

RESUMO

By using an in vitro model of antibody-mediated demyelination, we investigated the relationship between tumor necrosis factor-alpha (TNF-alpha) and heat shock protein (HSP) induction with respect to oligodendrocyte survival. Differentiated aggregate cultures of rat telencephalon were subjected to demyelination by exposure to antibodies against myelin oligodendrocyte glycoprotein (MOG) and complement. Cultures were analyzed 48 hr after exposure. Myelin basic protein (MBP) expression was greatly decreased, but no evidence was found for either necrosis or apoptosis. TNF-alpha was significantly up-regulated. It was localized predominantly in neurons and to a lesser extent in astrocytes and oligodendrocytes, and it was not detectable in microglial cells. Among the different HSPs examined, HSP32 and alphaB-crystallin were up-regulated; they may confer protection from oxidative stress and from apoptotic death, respectively. These results suggest that TNF-alpha, often regarded as a promoter of oligodendroglial death, could alternatively mediate a protective pathway through alphaB-crystallin up-regulation.


Assuntos
Anticorpos/efeitos adversos , Cristalinas/metabolismo , Doenças Desmielinizantes/metabolismo , Oligodendroglia/efeitos dos fármacos , Telencéfalo/citologia , Fator de Necrose Tumoral alfa/metabolismo , 2',3'-Nucleotídeo Cíclico Fosfodiesterases/metabolismo , Animais , Apoptose/fisiologia , Western Blotting/métodos , Células Cultivadas , Proteínas do Sistema Complemento/efeitos adversos , Doenças Desmielinizantes/induzido quimicamente , Modelos Animais de Doenças , Interações Medicamentosas , Embrião de Mamíferos , Proteína Glial Fibrilar Ácida/metabolismo , Heme Oxigenase (Desciclizante)/metabolismo , Heme Oxigenase-1 , Imuno-Histoquímica/métodos , Hibridização In Situ/métodos , Proteína Básica da Mielina/genética , Proteína Básica da Mielina/metabolismo , Proteínas da Mielina , Glicoproteína Associada a Mielina/imunologia , Glicoproteína Mielina-Oligodendrócito , Necrose/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Ratos , Regulação para Cima
2.
J Neurosci Res ; 71(2): 246-55, 2003 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-12503087

RESUMO

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a member of the nuclear hormone superfamily originally characterized as a regulator of adipocyte differentiation and lipid metabolism. In addition, PPAR-gamma has important immunomodulatory functions. If the effect of PPAR-gamma's activation in T-cell-mediated demyelination has been recently demonstrated, nothing is known about the role of PPAR-gamma in antibody-induced demyelination in the absence of T-cell interactions and monocyte/macrophage activation. Therefore, we investigated PPAR-gamma's involvement by using an in vitro model of inflammatory demyelination in three-dimensional aggregating rat brain cell cultures. We found that PPAR-gamma was not constitutively expressed in these cultures but was strongly up-regulated following demyelination mediated by antibodies directed against myelin oligodendrocyte glycoprotein (MOG) in the presence of complement. Pioglitazone, a selective PPAR-gamma agonist, partially protected aggregates from anti-MOG demyelination. Heat shock responses and the expression of the proinflammatory cytokine tumor necrosis factor-alpha were diminished by pioglitazone treatment. Therefore, pioglitazone protection seems to be linked to an inhibition of glial cell proinflammatory activities following anti-MOG induced demyelination. We show that PPAR-gamma agonists act not only on T cells but also on antibody-mediated demyelination. This may represent a significant benefit in treating multiple sclerosis patients.


Assuntos
Hipoglicemiantes/farmacologia , Neuroglia/efeitos dos fármacos , Oxigenases , Receptores Citoplasmáticos e Nucleares/agonistas , Tiazóis/farmacologia , Tiazolidinedionas , Fatores de Transcrição/agonistas , Análise de Variância , Animais , Anticorpos Monoclonais/farmacologia , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Células Cultivadas , Proteínas do Sistema Complemento/imunologia , Cristalinas/efeitos dos fármacos , Cristalinas/metabolismo , Doenças Desmielinizantes/induzido quimicamente , Relação Dose-Resposta a Droga , Interações Medicamentosas , Embrião de Mamíferos , Gliceraldeído-3-Fosfato Desidrogenases/genética , Gliceraldeído-3-Fosfato Desidrogenases/metabolismo , Proteínas de Choque Térmico/efeitos dos fármacos , Proteínas de Choque Térmico/metabolismo , Heme Oxigenase (Desciclizante) , Imunoglobulina G/farmacologia , Técnicas In Vitro , Mediadores da Inflamação/fisiologia , Proteínas da Mielina , Glicoproteína Associada a Mielina/imunologia , Glicoproteína Mielina-Oligodendrócito , Neuroglia/fisiologia , Pioglitazona , RNA Mensageiro/biossíntese , Ratos , Receptores Citoplasmáticos e Nucleares/genética , Receptores Citoplasmáticos e Nucleares/fisiologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fatores de Transcrição/genética , Fatores de Transcrição/fisiologia , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismo , Regulação para Cima
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA